Intellia Therapeutics (NTLA) Competitor Comparison
We are evaluating the key criteria listed to compare Intellia Therapeutics (NTLA) against its competitors in the Biotechnology industry.
Market Capitalization
59 / 368Gross Profits
273 / 278Total Revenue
119 / 300EBITDA
321 / 337Free Cashflow
349 / 352Quick Ratio
87 / 357Earnings per Share
312 / 359Dividend yield
0 / 6Total Cash
30 / 358Performance 3 years
284 / 368Performance 5 years
119 / 368Performance 10 years
122 / 368Linearity 3 years
241 / 368Linearity 5 years
5 / 368Linearity 10 years
29 / 368Total Rank
163 / 368Dividend Rank
167 / 368Valuation Rank
209 / 368Piotroski Rank
196 / 368Muliplier Rank
125 / 368Performance 5 years - NTLA ranking 119 / 368
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.